Skip to content

Samsara Biocapital, LLC 13F Holdings · Q2 2026

Samsara Biocapital, LLC reported 24 securities worth $1.22B in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: SRRK (31.16%), ALMS (14.67%), MLYS (13.01%). Among its top 25 positions this quarter: 4 new, 2 added, 5 trimmed, 1 exited.

RankTickerCompanyValue% PortfolioSharesAction
1SRRKSCHOLAR ROCK HLDG CORP$379.4M31.16%6.9MHold
2ALMSALUMIS INC$178.6M14.67%6.3MHold
3MLYSMINERALYS THERAPEUTICS INC$158.4M13.01%5.9MHold
4SEPNSEPTERNA INC$105.5M8.66%3.1MHold
5ALMRALAMAR BIOSCIENCES INC$67.2M5.52%2.5MNew
6NGNENEUROGENE INC$54.0M4.44%1.7MHold
7KLRSKALARIS THERAPEUTICS INC$52.4M4.31%12.9MTrimmed
8SGPSPYGLASS PHARMA INC$47.0M3.86%2.1MHold
9STROSUTRO BIOPHARMA INC$35.3M2.90%1.1MHold
10IVAINVENTIVA SA$23.9M1.96%6.3MAdded
11JBIOJADE BIOSCIENCES INC$16.4M1.34%736,237Trimmed
12PBLSPARABILIS MEDICINES INC$15.2M1.25%556,044New
13VTVTVTV THERAPEUTICS INC$11.2M0.92%298,496Hold
14AQSTAQUESTIVE THERAPEUTICS INC$10.4M0.85%2.5MHold
15NKTXNKARTA INC$9.9M0.82%3.5MHold
16ARTVARTIVA BIOTHERAPEUTICS INC$9.3M0.76%954,861New
17RANIRANI THERAPEUTICS HLDGS INC$7.9M0.65%10.4MAdded
18AGMBAGOMAB THERAPEUTICS NV$7.8M0.64%600,000Hold
19ABVXABIVAX SA$7.3M0.60%55,095Trimmed
20XFORX4 PHARMACEUTICALS INC$6.5M0.54%1.4MTrimmed
21ELOXELOXX PHARMACEUTICALS INC$5.6M0.46%400,000New
22CHRSCOHERUS ONCOLOGY INC$4.8M0.39%3.4MHold
23UPBUPSTREAM BIO INC$2.4M0.20%353,717Trimmed
24GOSSGOSSAMER BIO INC$1.2M0.10%7.2MHold
25ACLXARCELLX INC$00.00%0Exited

Source: SEC Form 13F filings · as of 2026-06-30

Every position in this 13F-HR, with its change from the prior quarter.

13F holdings, latest quarter

SourceSEC EDGAR13F-HR